Dosing and therapeutic drug monitoring of voriconazole in bottlenose dolphins (Tursiops truncatus)
Authors:
- 4 October 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 55 (2) , 155-163
Abstract
Bottlenose dolphins (Tursiops truncatus) can suffer from fungal infections, which can be treated with voriconazole. In common practice, the voriconazole doses are extrapolated from human doses by adjusting for body weight only, because no dose regimen is available yet. Therefore, the aim of this study was to define a dose regimen for voriconazole in bottlenose dolphins. Dolphins treated with voriconazole between November 2005 and September 2015 at the Dolfinarium Harderwijk, the Netherlands, and TDM was performed were included. Voriconazole plasma concentrations were analyzed with a HPLC-UV method. A population pharmacokinetic model was developed using Mw/Pharm in which the elimination rate constant (ke) and apparent total distribution volume (Vd) was calculated. The loading dose was calculated using the central Vd (Vdc). The maintenance dose was simulated in Mw/Pharm using ke and total Vd. Eleven dolphins were included. Ke was estimated to be 0.0026 ± 0.0007 hour−1 (mean ± SD), Vd 5.3 ± 3.2 l/kg (mean ± SD), and Vdc ranged between 1.8 and 2.8 l/kg (mean 2.2 l/kg). In order to obtain a median top plasma concentration of 5 mg/l, the loading dose was calculated to be 10 mg/kg (range 9.0–14.2 mg/kg) divided in three administrations (3.3 mg/kg every 24 hours). The maintenance dose was calculated to be 4 mg/kg once a week (range 1.7–6.0 mg/kg); 17% of the dolphins did not reach the therapeutic window of 1–5 mg/l without TDM. A TDM-guided dosing algorithm was developed in order to obtain therapeutic plasma concentrations in this population.Keywords
This publication has 25 references indexed in Scilit:
- Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levelsMedical Mycology, 2016
- Voriconazole pharmacokinetics and exposure–response relationships: Assessing the links between exposure, efficacy and toxicityInternational Journal of Antimicrobial Agents, 2014
- The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazoleAmerican Journal of Hematology, 2013
- Current Concepts in Antifungal PharmacologyMayo Clinic Proceedings, 2011
- Antifungal Activity of Itraconazole and Voriconazole against Clinical Isolates Obtained from Animals with MycosesNippon Ishinkin Gakkai Zasshi, 2009
- Therapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic ConsiderationsTherapeutic Drug Monitoring, 2008
- Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety OutcomesClinical Infectious Diseases, 2008
- Pharmacokinetic/Pharmacodynamic Profile of VoriconazoleClinical Pharmacokinetics, 2006
- THE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMANDrug Metabolism and Disposition, 2003
- Antifungal agents: mechanisms of actionTrends in Microbiology, 2003